Search
Search Results
-
Sirolimus for vascular anomalies in the first year of life: a systematic review
Evidence on effectiveness and safety of sirolimus in congenital vascular anomalies in infancy is lacking. We aim to systematically review the...
-
Sirolimus is effective for refractory/relapsed idiopathic multicentric Castleman disease: A single-center, retrospective study
Refractory/relapsed idiopathic multicentric Castleman disease (R/R iMCD) has limited treatment options. With studies showing increased mTOR...
-
Real-World Data on the Use of Sirolimus in Asian Children with Vascular Malformations
ObjectivesThe management of vascular malformations is complex and challenging. This study aimed to explore efficacy, plasma trough concentrations of...
-
Fibroadipose vascular anomaly successfully treated with sirolimus: experience in 3 children
PurposeFibro-adipose vascular anomaly (FAVA) is a unique lesion composed of dense fibro-fatty tissue and slow-flow vascular malformations and is...
-
Targeted treatment in complex lymphatic anomaly: a case of synergistic efficacy of trametinib and sirolimus
Repurposing anticancer drugs to vascular malformations has significantly improved patient outcomes. Complex Lymphatic Anomalies (CLA) are part of the...
-
Oral antibiotic prophylaxis for infection in patients with vascular anomalies receiving sirolimus treatment: a multicenter retrospective study
ObjectivesPatients with vascular anomalies (VAs) who receive oral sirolimus may be at high risk of infectious complications. Antibiotic prophylaxis...
-
Sirolimus treatment for paediatric head and neck lymphatic malformations: a systematic review
PurposeThis PRISMA-compliant systematic review aimed to assess risks and benefits of sirolimus treatment for paediatric lymphatic malformations by...
-
Sirolimus can promote the disappearance of renal angiomyolipoma associated with tuberous sclerosis complex: a prospective cohort study
BackgroundRenal angiomyolipoma (RAML) is the most common kidney lesion in patients with tuberous sclerosis complex (TSC), affecting about 80% of...
-
Two cases of successful sirolimus treatment for patients with activated phosphoinositide 3-kinase δ syndrome 1
BackgroundActivated phosphoinositide3-kinase (PI3K) δ syndrome 1 (APDS1) is a novel inborn errors of immunity (IEIs) caused by heterozygous gain of...
-
Safety and efficacy of sirolimus in recurrent intravenous leiomyomatosis, pulmonary benign metastatic leiomyomatosis, and leiomyomatosis peritonealis disseminata: a pilot study
BackgroundIntravenous leiomyomatosis (IVL), pulmonary benign metastatic leiomyomatosis (PBML), and leiomyomatosis peritonealis disseminata (LPD) are...
-
Sirolimus as a second-line treatment for Graves’ orbitopathy
ObjectivesA beneficial effect of sirolimus in Graves’ orbitopathy (GO) was reported, suggesting a possible use in clinical practice. We conducted an...
-
Successful Management of Retropharyngeal Lymphangioma with Stridor Using Sirolimus: A Case Report
Lymphatic malformations (LMs) are one of the congenital malformations of the lymphatic system in the body. The patient usually presents with head and...
-
Tremor Induced by Cyclosporine, Tacrolimus, Sirolimus, or Everolimus: A Review of the Literature
Calcineurin inhibitors such as cyclosporine and tacrolimus are immunosuppressant drugs that are known to induce tremors. Non-calcineurin inhibitors...
